PURPOSE: To evaluate the maximum-tolerated dose and the clinical efficacy of @entity1259 in @entity1 with @entity242 . @entity1 AND METHODS: Sixty-one @entity1 were treated at three different @entity1259 dose levels: 140 mg/m(2) (six @entity1 ), 160 mg/m(2) (52 @entity1 ), and 180 mg/m(2) (three @entity1 ). Cycles were repeated every 3 weeks for a maximum of eight cycles. The first two dose levels proved to be feasible and safe without @entity137 ( @entity137 ). Because the first three @entity1 entering the third dose level experienced @entity137 , subsequent @entity1 received the next lower dose level. RESULTS: The overall response rate was 44% (95% confidence interval, +/- 12%), with six complete (10%) and 21 partial (34%) responses. Responses seemed related to @entity1259 dose level, because the response rate was 17%, 44%, and 100% for the three dose levels (chi(2) test for trend, P =.02). Median response duration, median time to progression, and median overall survival were 10, 8, and 15 months, respectively. Myelosuppression was the most frequent side effect, with grade 3 or 4 @entity1398 occurring in 79% of the @entity1 ; 31% of @entity1 were febrile. Nonhematologic @entity137 was mainly grades 1 and 2. The mean @entity1259 dose-intensity was 49 mg/m(2) per week. CONCLUSION: The third @entity1259 dose level (180 mg/m(2)) was the maximum-tolerated dose. The recommended drug dose for clinical use is 160 mg/m(2) every 3 weeks with @entity1583 support. Single high-dose @entity1259 is effective as first-line treatment and should be preferentially used whenever a high response rate is important to allow the resection of an otherwise unresectable disease or whenever it might result in a significant symptomatic benefit.

Increasing single @entity1259 doses in advanced soft tissue XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'DLT', 'dose-limiting toxicity'] @entity242 :: ('MESH:D012509', 'Disease') :: ['advanced soft tissue sarcoma'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematopoietic']
@entity242 :: (MESH:D012509,Disease) :: ['sarcomas']
